Previous 10 | Next 10 |
Lucid’s first commercial payer agreement provides in-network access and payment for its EsoGuard ® DNA test to over 8 million covered lives Lucid Diagnostics Inc. (Nasdaq: LUCD ) (“Lucid”, the “Company”) a commercial-st...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Company conference call and webcast at 4:30 PM EDT Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that the ...
Updated American College of Gastroenterology clinical guideline supports esophageal precancer screening with EsoGuard ® on samples collected with EsoCheck ® Proposed Medicare Local Coverage Determination published by Palmetto GBA’s MolDX Program trigge...
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Dr. Lishan Aklog, Chairman and CEO,...
Conference call to be held today at 4:30 PM EDT PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health...
Lucid Diagnostics Inc. (LUCD) Q4 2021 Earnings Conference Call March 28, 2022 16:30 ET CompanyParticipants Adrian Miller - Vice President of Investor Relations Dennis McGrath - Chief Financial Officer Lishan Aklog - Chairman & Chief Executive Officer Conference Call Participants Kyle Miks...
Lucid Diagnostics (NASDAQ:LUCD) reported prelim. Q4 non-GAAP EPS of -$0.22 vs. consensus estimate of -$0.20. Prelim. Q4 revenue was $0.3M vs. consensus estimate of $0.4M. LUCD reported prelim. 2021 non-GAAP EPS of -$0.96 vs. consensus estimate of -$1.37. Prelim. 2021 revenue was $0....
Lucid Diagnostics press release (NASDAQ:LUCD): Q4 Non-GAAP EPS of -$0.22. Revenue of $0.3M (-40.0% Y/Y). Lucid had cash and cash equivalents of $53.7 million as of December 31, 2021, compared to $0.1 million as of December 31, 2020. For further details see: Lucid Diagnostics Non-GA...
Conference call to be held today at 4:30 PM EDT Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq:...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Inc. Company Name:
LUCD Stock Symbol:
NASDAQ Market:
Lucid Diagnostics Inc. Website:
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire Quarterly EsoGuard ® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("L...
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...